Danube Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Biotech start-up Danube Pharmaceuticals Inc. has in-licensed what it calls the only dual-mechanism of action, orally available small molecule in clinical testing for glaucoma, a leading cause of irreversible blindness worldwide.
You may also be interested in...
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.